Cover Image

Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis

While antifibrotic drugs significantly decrease lung function decline in idiopathic pulmonary fibrosis (IPF), there is still an unmet need to halt disease progression. Antioxidative therapy with N-acetylcysteine (NAC) is considered a potential additional therapy that can be combined with antifibroti...

Full description

Saved in:
Bibliographic Details
Main Authors: Shi, Hanyu (Author) , Yin, Dawei (Author) , Bonella, Francesco (Author) , Kreuter, Michael (Author) , Oltmanns, Ute (Author) , Li, Xuren (Author) , Peng, Shouchun (Author) , Wei, Luqing (Author)
Format: Article (Journal)
Language:English
Published: 07 May 2020
In: BMC pulmonary medicine
Year: 2020, Volume: 20, Issue: 1
ISSN:1471-2466
DOI:10.1186/s12890-020-1121-2
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12890-020-1121-2
Get full text
Author Notes:Hanyu Shi, Dawei Yin, Francesco Bonella, Michael Kreuter, Ute Oltmanns, Xuren Li, Shouchun Peng, Luqing Wei
Description
Summary:While antifibrotic drugs significantly decrease lung function decline in idiopathic pulmonary fibrosis (IPF), there is still an unmet need to halt disease progression. Antioxidative therapy with N-acetylcysteine (NAC) is considered a potential additional therapy that can be combined with antifibrotics in some patients in clinical practice. However, data on the efficacy, tolerability, and safety of this combination are scarce. We performed a systematic review and meta-analysis to appraise the safety, tolerability, and efficacy of the combination compared to treatment with pirfenidone alone.
Item Description:Gesehen am 08.06.2020
Physical Description:Online Resource
ISSN:1471-2466
DOI:10.1186/s12890-020-1121-2

Similar Items